A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : APCR / activated protein C resistance

[Related PubMed/MEDLINE]
Total Number of Papers: 203
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   APCR  (>> Co-occurring Abbreviation)
Long Form:   activated protein C resistance
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods. FVL
2020 Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation. APTT, dRVVT
2020 Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of aβ2GPI and aPS/PT antibodies. abeta2GPI, APS, IQR, NPP
2020 Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. ---
2020 Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance. ETP, nAPCsr
2020 Prothrombotic Factors Have Significant Association with Arterial and Venous Strokes in Indian Tamilians. ATIII, CVT, FVL, Hcys, IS
2019 DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients. DOACs, FVL, RVVT, VTE
2019 Inherited thrombophilia in unprovoked venous thromboembolism: Is non 'O' blood group an additional culprit in Indian patients? Hcy, PC, PS, VTE
2019 Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. CHC, ETP
10  2018 Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden. ---
11  2018 Reduced Protein C Global Assay Levels in Infertile Women with in vitro Fertilization Failure: A Pilot Study. ART, IVF, PCAT-NR
12  2017 Adverse pregnancy outcomes and inherited thrombophilia. IUGR, PE
13  2017 Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden: A Comparison of Institutional and National Provider Practices. FVL, OLDW
14  2017 Laboratory Testing for Activated Protein C Resistance (APCR). APC, FVL
15  2017 Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers. FVL, RIV
16  2017 Primary Thrombophilia in Mexico XI: Activated Protein C Resistance Phenotypes are Multifactorial. DOACs
17  2017 Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden). FVL, FVL-HET
18  2016 Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay. RVVT
19  2016 Association between in vitro fertilization outcomes and inherited thrombophilias: a meta-analysis. CI, FVL, IR, IVF, MTHFR, RR
20  2016 Prevalence and role of antithrombin III, protein C and protein S deficiencies and activated protein C resistance in Kosovo women with recurrent pregnancy loss during the first trimester of pregnancy. ATIII, PC, PS, RPL
21  2016 Use of a systematic risk analysis method (FMECA) to improve quality in a clinical laboratory procedure. RPN
22  2016 [Correlation of Thrombosis and Prothrombotic State with Coagulation Factor V Gene Polymorphism and APCR. HHcy]. COPD, HHcy, RFLP
23  2015 Activated Protein C-Resistance Determination and Vascular Access Thrombosis in Populations with High Prevalence of Factor V Leiden. OR
24  2015 Maximising the diagnostic potential of APTT-based screening assays for activated protein C resistance. CAPC-R, LA
25  2015 Prevalence of Factor V Genetic Variants Associated With Indian APCR Contributing to Thrombotic Risk. APC, DVT, PCR, SNPs
26  2014 Effect of freezing plasma at -20C for 2 weeks on prothrombin time, activated partial thromboplastin time, dilute Russell viper venom time, activated protein C resistance, and D-dimer levels. APTT, dRVVT, PT
27  2014 Haemostatic Parameters in Patients with Behcet's Disease. Ag, AT, BD, RiCof, vWF
28  2014 Profile of prothrombotic factors in Indian children with ischemic stroke. aCL, ATIII, FVL, Ig, LA, MTHFR, PC, PS
29  2013 Activated protein C resistance in Behcet's disease. ---
30  2013 An improved algorithm for activated protein C resistance and factor V Leiden screening. ---
31  2013 Clinical profile, common thrombophilia markers and risk factors in 85 young Indian patients with arterial thrombosis. AT
32  2013 Placental prothrombin mRNA levels in APC resistance (APCR) women with increased placental fibrin deposition. ---
33  2013 Prevalence of the Factor V E666D Mutation and Its Correlation With Activated Protein C Resistance in the Chinese Population. FV, VTE
34  2012 Advances in laboratory testing for thrombophilia. ---
35  2012 Coagulation inhibitors and activated protein C resistance in recurrent pregnancy losses in Indian women. APLA, RPL
36  2012 Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway. APS, AUCnr, FVL, PC/PS, TGT, VTE
37  2012 Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. MM, VEGF, VTE
38  2012 Prevalence of activated protein C resistance (Factor V Leiden) in Lagos, Nigeria. APC-V ratio
39  2012 Superficial vein thrombosis in patients with varicose veins: role of thrombophilia factors, age and body mass. BMI, CI, OR, PC, PLG, PS, SVT, VVs
40  2011 A clinical audit of congenital thrombophilia investigation in tertiary practice. AT, FVL, PC, PS
41  2011 A possible role for familial thrombophilia in women with polycystic ovarian syndrome. PCOS
42  2011 Acquired activated protein C resistance caused by lupus anticoagulants. LA
43  2011 Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women. MTHFR, PC, PS, SNP
44  2011 Activated protein C resistance and its correlation with thrombophlebitis in Behcet's disease. BD
45  2011 Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. MGUS, VTE
46  2011 Lupus anticoagulant interference in activated protein C resistance testing: in vitro phenomenon or in vivo pathophysiologic effect? FV, LA
47  2011 Natural coagulation inhibitors and active protein c resistance in preeclampsia. ATIII, FPS, PC
48  2011 The influence of maternal Lewis, Secretor and ABO(H) blood groups on fetal growth restriction. CI, FGR, OR, vWF
49  2010 A novel mutation (g2172-->c) in the factor V gene in a Chinese family with hereditary activated protein C resistance. FV, VTE
50  2010 APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women. EPL, FVL, GMPD, IGUR, PCR-REA, PIH
51  2010 Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality. APTT, CCHF, INR, PT
52  2010 High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait. FVL, VTE
53  2010 Prevalence of common thrombophilia markers and risk factors in Indian patients with primary venous thrombosis. ---
54  2010 Resistance to activated protein C and ischemic arterial disease in a young man. ---
55  2010 Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event. ACS, APTT, CHD, CI, FVIII, PT, SCAD
56  2010 Thrombophilia investigation in Malaysian women with recurrent pregnancy loss. FVL, RPL
57  2010 Usefulness of factor V Leiden mutation testing in clinical practice. FVL, VTE
58  2009 Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus. aPLs, CI, OR, SLE
59  2009 Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. abeta2GPI, AE and VE, aPL, vWF
60  2009 Hypercoagulable state and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with beta-thalassemia major in Kuwait. AT, LA, MTHFR, PC, PS
61  2009 Increased thrombophilic tendency in pediatric cystic fibrosis patients. CF
62  2009 Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease. IBD
63  2009 [Activated protein C resistance and factor V Leiden: clinical interest]. ---
64  2008 Activated protein C resistance (APCR) and placental fibrin deposition. IUGR, MSB
65  2008 Determinants and associations of homocysteine and prothrombotic risk factors in Kuwaiti patients with cerebrovascular accident. CVAs, GFR, tHcy
66  2008 Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. CR, OC, SHBG
67  2008 The diagnostic dilemma: dual presentations of clinical mucosal bleeding and venous thrombosis associated with the presence of thrombophilia markers and mild reduction in von Willebrand factor. FVL, MTHFR, QAP, VWD, vWF
68  2007 A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms. DVT, FV, VTE
69  2007 A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability. CEE/MPA, HT, TFPI, VTE
70  2007 Activated protein C resistance and factor V Leiden in Mexico. ---
71  2007 Activated protein C resistance in cord blood from healthy and complicated newborns. ---
72  2007 Activated protein C resistance in patients with arterial ischemic stroke. IS, RF
73  2007 Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR. RM, SNPs
74  2007 Single inherited thrombophilias and adverse pregnancy outcomes. AT, HELLP, MTHFR
75  2007 The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion. IF, RSA, Tg, TPO, TSH, UI
76  2007 [Analysis of activated protein C resistance, factor V coagulation activity and gene polymorphisms in patients with venous thromboembolism]. FV, VTE
77  2007 [Hypercoagulable state due to acquired protein C resistance, harbinger of colonic neoplasm?]. DVT, FVL
78  2007 [Primary thrombophilia in Mexico. VI: lack of statistical association among the inherited thrombophilic conditions]. MTHFR, SPS
79  2006 Acquired activated protein C resistance and thrombosis in multiple myeloma patients. APC, APTT, DVT, MM
80  2006 Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population. APTT, ATIII, DD, ELISA, FIB, Hcy, ON, PAI, PC, PLG, SARS, vWF
81  2006 Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation. APC, APTT, FVL
82  2006 Factor V Leiden as a common genetic risk factor for venous thromboembolism. FVL
83  2006 Plasma cell leukemia: a rare condition. MM, PCL, PPCL, sPCL
84  2006 The Leiden mutation and activated protein C resistance as risk factors for disseminated intravascular coagulation in acutely poisoned patients. DIC
85  2006 Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion. FII, FVL, MTHFR, RSA
86  2006 [Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis]. APTT, ATIII, DD, FIB, PAI, PC, PLG, SARS, vWF
87  2006 [Role of gene polymorphism in development of thromboses]. ---
88  2005 Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies. ACA, anti-beta2GP-I, APTT, LA
89  2005 Activated protein C resistance: the influence of ABO-blood group, gender and age. APC, APTT, RVVT
90  2005 Effects of anticoagulation protein defect in maternal plasma on spontaneous abortion. ATIII, FV
91  2005 Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy. PC, PS
92  2005 High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. ---
93  2005 Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. AT, PC, PS, UK NEQAS
94  2005 Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology. AT, CVs, LA, PC, PS, RVVT
95  2005 Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma. FV
96  2005 Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients. ---
97  2005 Protein Z levels and central retinal vein or artery occlusion. ACA, CRAO, CRVO, LAC
98  2005 The factor V Glu1608Lys mutation is recurrent in familial thrombophilia. RFLP, rFV1608Lys
99  2005 Thrombophilia and first arterial ischaemic stroke: a systematic review. AIS, AT, OR
100  2005 Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. PAI-1, TAT III, tPA